MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation

European Journal of Pharmacology

Volumn 608, Issue 1-3, 2009, Pages 84-90

  Koeberle, Andreas ^a   Siemoneit, Ulf ^a   Northoff, Hinnak ^b   Hofmann, Bettina ^c   Schneider, Gisbert ^c   Werz, Oliver ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

5 Lipoxygenase; Cyclooxygenase; Leukotriene; MK 886; Platelet aggregation; Prostaglandin

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LEUKOTRIENE; PROSTAGLANDIN; THROMBIN; THROMBOXANE B2;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME ISOLATION; HUMAN; HUMAN CELL; INFLAMMATION; LUNG NON SMALL CELL CANCER; MOLECULAR DOCKING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN BONDING; INDOLES; INHIBITORY CONCENTRATION 50; LIPOXYGENASE INHIBITORS; LUNG NEOPLASMS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; SHEEP;

EID: 62949170825     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.02.023     Document Type: Article

References (54)

1. Akarsu E.S., and Mamuk S. Escherichia coli lipopolysaccharides produce serotype-specific hypothermic response in biotelemetered rats. Am. J. Physiol., Regul. Integr. Comp. Physiol. 292 (2007) R1846-R1850
2. Albert D., Zundorf I., Dingermann T., Muller W.E., Steinhilber D., and Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem. Pharmacol. 64 (2002) 1767-1775
3. Anderson K.M., Seed T., Plate J.M., Jajeh A., Meng J., and Harris J.E. Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leuk. Res. 19 (1995) 789-801
4. Asano K., Lilly C.M., and Drazen J.M. Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. Am. J. Physiol. 271 (1996) L126-L131
5. Azab A.N., and Kaplanski J. Involvement of eicosanoids in the hypothermic response to lipopolysaccharide during endotoxemia in rats. Prostaglandins Leukot. Essent. Fat. Acids 70 (2004) 67-75
6. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The protein data bank. Nucleic Acids Res. 28 (2000) 235-242
7. Capdevila J.H., Morrow J.D., Belosludtsev Y.Y., Beauchamp D.R., DuBois R.N., and Falck J.R. The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathione peroxidase(s). Biochemistry 34 (1995) 3325-3337
8. Claria J., and Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr. Pharm. Des. 11 (2005) 3431-3447
9. Claveau D., Sirinyan M., Guay J., Gordon R., Chan C.C., Bureau Y., Riendeau D., and Mancini J.A. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J. Immunol. 170 (2003) 4738-4744
10. Datta K., Biswal S.S., and Kehrer J.P. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem. J. 340 Pt 2 (1999) 371-375
11. Datta K., Biswal S.S., Xu J., Towndrow K.M., Feng X., and Kehrer J.P. A relationship between 5-lipoxygenase-activating protein and bcl-xL expression in murine pro-B lymphocytic FL5.12 cells. J. Biol. Chem. 273 (1998) 28163-28169
12. DeLano W.L. The PyMOL Molecular Graphics System (2002)
13. Dixon R.A., Diehl R.E., Opas E., Rands E., Vickers P.J., Evans J.F., Gillard J.W., and Miller D.K. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343 (1990) 282-284
14. Evans J.F., Ferguson A.D., Mosley R.T., and Hutchinson J.H. What's all the FLAP about? 5-Lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. 29 (2008) 72-78
15. Farivar-Mohseni H., Kandzari S.J., Zaslau S., Riggs D.R., Jackson B.J., and McFadden D.W. Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. Am. J. Surg. 188 (2004) 505-510
16. Ferguson A.D., McKeever B.M., Xu S., Wisniewski D., Miller D.K., Yamin T.T., Spencer R.H., Chu L., Ujjainwalla F., Cunningham B.R., Evans J.F., and Becker J.W. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317 (2007) 510-512
17. Ford-Hutchinson A.W. Leukotriene antagonists and inhibitors: clinical applications. Adv. Prostaglandin Thromboxane Leukotriene Res. 23 (1995) 69-74
18. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
19. Geiger J. Inhibitors of platelet signal transduction as anti-aggregatory drugs. Expert Opin. Investig. Drugs 10 (2001) 865-890
20. Ghosh J., and Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13182-13187
21. Gillard J., Ford-Hutchinson A.W., Chan C., Charleson S., Denis D., Foster A., Fortin R., Leger S., McFarlane C.S., Morton H., et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. 67 (1989) 456-464
22. Guerrero A.T., Verri Jr. W.A., Cunha T.M., Silva T.A., Schivo I.R., Dal-Secco D., Canetti C., Rocha F.A., Parada C.A., Cunha F.Q., and Ferreira S.H. Involvement of LTB4 in zymosan-induced joint nociception in mice: participation of neutrophils and PGE2. J. Leukoc. Biol. 83 (2008) 122-130
23. Gugliucci A., Ranzato L., Scorrano L., Colonna R., Petronilli V., Cusan C., Prato M., Mancini M., Pagano F., and Bernardi P. Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. J. Biol. Chem. 277 (2002) 31789-31795
24. Halgren T.A. Merck molecular force field 1. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 5 (1996) 490-519
25. Hammamieh R., Sumaida D., Zhang X., Das R., and Jett M. Control of the growth of human breast cancer cells in culture by manipulation of arachidonate metabolism. BMC Cancer 7 (2007) 138
26. Harman C.A., Turman M.V., Kozak K.R., Marnett L.J., Smith W.L., and Garavito R.M. Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides. J. Biol. Chem. 282 (2007) 28096-28105
27. Hofacker A., Coste O., Nguyen H.V., Marian C., Scholich K., and Geisslinger G. Downregulation of cytosolic prostaglandin E2 synthase results in decreased nociceptive behavior in rats. J. Neurosci. 25 (2005) 9005-9009
28. 2+ mobilization and synergistic P2Y12 receptor activation. J. Biol. Chem. 281 (2006) 26665-26674
29. Jones G., Willett P., and Glen R.C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 245 (1995) 43-53
30. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727-748
31. Kawai S., Nishida S., Kato M., Furumaya Y., Okamoto R., Koshino T., and Mizushima Y. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur. J. Pharmacol. 347 (1998) 87-94
32. Kehrer J.P., Biswal S.S., La E., Thuillier P., Datta K., Fischer S.M., and Vanden Heuvel J.P. Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem. J. 356 (2001) 899-906
33. Koeberle A., Siemoneit U., Buhring U., Northoff H., Laufer S., Albrecht W., and Werz O. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J. Pharmacol. Exp. Ther. 326 (2008) 975-982
34. Kundu N., and Fulton A.M. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 62 (2002) 2343-2346
35. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., Isakson P.C., and Stallings W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384 (1996) 644-648
36. Lam B.K., Penrose J.F., Freeman G.J., and Austen K.F. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7663-7667
37. Mancini J.A., Abramovitz M., Cox M.E., Wong E., Charleson S., Perrier H., Wang Z., Prasit P., and Vickers P.J. 5-Lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 318 (1993) 277-281
38. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., and Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90 (1993) 11693-11697
39. Picot D., Loll P.J., and Garavito R.M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367 (1994) 243-249
40. Ponder J.W., and Case D.A. Force fields for protein simulations. Adv. Protein Chem. 66 (2003) 27-85
41. Samuelsson B., Morgenstern R., and Jakobsson P.J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 59 (2007) 207-224
42. Schuller H.M., Zhang L., Weddle D.L., Castonguay A., Walker K., and Miller M.S. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J. Cancer Res. Clin. Oncol. 128 (2002) 525-532
43. Sekiya F., Takagi J., Usui T., Kawajiri K., Kobayashi Y., Sato F., and Saito Y. 12S-hydroxyeicosatetraenoic acid plays a central role in the regulation of platelet activation. Biochem. Biophys. Res. Commun. 179 (1991) 345-351
44. Seuter F. Inhibition of platelet aggregation by acetylsalicylic acid and other inhibitors. Haemostasis 5 (1976) 85-95
45. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 69 (2000) 145-182
46. Sotiriou C., Lacroix M., Lagneaux L., Berchem G., and Body J.J. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11. Anticancer Res. 19 (1999) 2997-3006
47. Stanke-Labesque F., Hardy G., Caron F., Cracowski J.L., and Bessard G. Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats. Br. J. Pharmacol. 140 (2003) 186-194
48. Steinhilber D. 5-Lipoxygenase: enzyme expression and regulation of activity. Pharm. Acta Helv. 69 (1994) 3-14
49. Stika J., Vondracek J., Hofmanova J., Simek V., and Kozubik A. MK-886 enhances tumour necrosis factor-alpha-induced differentiation and apoptosis. Cancer Lett. 237 (2006) 263-271
50. Tagari P., Brideau C., Chan C., Frenette R., Black C., and Ford-Hutchinson A. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. Agents Actions 40 (1993) 62-71
51. Vanags D.M., Larsson P., Feltenmark S., Jakobsson P.J., Orrenius S., Claesson H.E., and Aguilar-Santelises M. Inhibitors of arachidonic acid metabolism reduce DNA and nuclear fragmentation induced by TNF plus cycloheximide in U937 cells. Cell. Death. Differ. 4 (1997) 479-486
52. Weisel M., Proschak E., and Schneider G. PocketPicker: analysis of ligand binding-sites with shape descriptors. Chem. Cent. J. 1 (2007) 7
53. Wu X., Biswal S.S., and Kehrer J.P. Roles of 5-lipoxygenase activating protein in cell proliferation and apoptosis. Cell. Biol. Toxicol. 19 (2003) 135-143
54. Yip-Schneider M.T., Barnard D.S., Billings S.D., Cheng L., Heilman D.K., Lin A., Marshall S.J., Crowell P.L., Marshall M.S., and Sweeney C.J. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21 (2000) 139-146